Current concepts in the management of Parkinson disease

Medical Journal of Australia

Volumn 192, Issue 3, 2010, Pages 144-149

  Hayes, Michael W ^a   Fung, Victor S ^b,c   Kimber, Thomas E ^d   O'Sullivan, John D ^e,f  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BENZATROPINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; DOMPERIDONE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ERGOLINE DERIVATIVE; FLUDROCORTISONE; LEVODOPA; MACROGOL; MIDODRINE; NORTRIPTYLINE; OXYBUTYNIN; PERGOLIDE; PRAMIPEXOLE; PYRIDOSTIGMINE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SILDENAFIL; TOLTERODINE; UNINDEXED DRUG; VARDENAFIL;

ANATOMICAL VARIATION; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; COGNITIVE DEFECT; CONSTIPATION; DISEASE COURSE; DROWSINESS; DRUG BLOOD LEVEL; ERECTILE DYSFUNCTION; FIBROSIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; IMPULSE CONTROL DISORDER; MICTURITION DISORDER; MORBIDITY; NAUSEA; NEUROPROTECTION; NEUROSURGERY; NOCTURIA; ORTHOSTATIC HYPERTENSION; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PALLIDOTOMY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSIOTHERAPY; REVIEW; SKIN NODULE; SPEECH THERAPY; THALAMOTOMY; TREATMENT RESPONSE;

EID: 77952410242     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03453.x     Document Type: Review

References (40)

1. Lang AE, Obeso JA. Current challenges in Parkinson's disease: restoring the nigro-striatal dopamine system will not suffice. Lancet Neurol 2004; 3: 309-316.
2. Living with Parkinson's disease: challenges and positive steps for the future. Canberra: Access Economics for Parkinson's Australia, 2007. http://www.parkinsons.org.au/media-advocacy/docs/pd-study.pdf (accessed Oct 2009).
3. Polymeropoulos MH, Lavendan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047. (Pubitemid 27443610)
4. Spillantini MG, Schmidt MI, Lee VM, et al. Alpha synuclein in Lewy bodies. Nature 1997; 388: 839-840.
5. Gasser T. Update on the genetics of Parkinson's disease. Mov Disord 2007; 22 Suppl 17: S343-S350.
6. Predborski S. Etiology and pathogenesis of Parkinson's disease. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. 5th ed. New York: Lippincott Williams & Wilkins, 2006: 77-92.
7. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211. (Pubitemid 36007810)
8. Hely M, Reid W, Adena M, et al. The Sydney Multicenter Study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844.
9. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-870. (Pubitemid 34279780)
10. Suchowersky O, Reich S, Perlmutter J, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Committee of the American Academy of Neurology. Neurology 2006; 66: 968-975. (Pubitemid 44044778)
11. Morrish PK, Sawle GV, Brooks DJ, et al. The rate of progression of Parkinson's disease. A longitudinal [18F]DOPA PET study. Adv Neurol 1996; 69: 427-431.
12. Lang AE. The progression of Parkinson disease: a hypothesis. Neurology 2007; 68: 948-952.
13. Suchowersky O, Gronseth G, Perlmutter J, et al. Practice parameter: neuro-protective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 976-982. (Pubitemid 44044779)
14. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society - European Section (MDS-ES). Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006; 13: 1170-1185. (Pubitemid 44581464)
15. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society - European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186-1202. (Pubitemid 44581465)
16. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004. Eur J Neurol 2004; 11: 577-581. (Pubitemid 39279947)
17. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996-1002. (Pubitemid 44044781)
18. Pahwa R, Factor S, Lyons K, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983-995. (Pubitemid 44044780)
19. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17: 60-67.
20. Keus S, Munneke M, Nijrake M, et al. Physical therapy in Parkinson's disease: evolution and future challenges. Mov Disord 2009; 24: 1-14.
21. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71: 474-480.
22. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: non-L-dopa responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-199.
23. Rascol O, Olanow CW. The effects of rasagiline in early Parkinson's disease: the ADAGIO delayed start trial. Mov Disord 2009; 24 Suppl 1: S275.
24. Schapira AH, Obeso JA. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006; 59: 559-562.
25. Obeso JA, Rodriguez-Oroz M, Marin C, et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004; 62 Suppl 1: S17-S30. (Pubitemid 38082849)
26. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community based study. Brain 2000; 123: 2297-2305.
27. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 2004; 62 Suppl 1: S56-S63. (Pubitemid 38082853)
28. Hughes A, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165-170. (Pubitemid 23131637)
29. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998; 65: 709-716. (Pubitemid 28486650)
30. Nyholm D, Askmark H, Gomes-Trollin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003; 26: 156-163. (Pubitemid 36676295)
31. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007; 22: 1145-1149. (Pubitemid 47067225)
32. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005; 128: 2240-2249. (Pubitemid 41407964)
33. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896-908. (Pubitemid 44315982)
34. Rodrigues JP, Walters SE, Watson P, et al. Globus pallidus stimulation in advanced Parkinson's disease. J Clin Neurosci 2007; 14: 208-215. (Pubitemid 46157010)
35. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson's disease: a randomized controlled trial. JAMA 2009; 301: 63-73.
36. Silberstein P, Bittar RG, Bole R, et al. Deep brain stimulation for Parkinson's disease: Australian referral guidelines. J Clin Neurosci 2009; 16: 1001-1008.
37. Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-245.
38. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson's disease and depression. Neurology 2009; 72: 886-892.
39. O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009; 23: 157-170.
40. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518. (Pubitemid 39603164)